ResMed Inc. (ASX:RMD) has dismissed KPMG LLP as its independent registered public accounting firm and appointed PricewaterhouseCoopers LLP as its replacement, effective for the fiscal year ending June 30, 2027, according to a Form 8-K filed with the Securities and Exchange Commission on August 17, 2026.

Key Points

  • KPMG LLP was dismissed as ResMed's principal accountant on August 13, 2026, following a competitive review process conducted by the Audit Committee.
  • PricewaterhouseCoopers LLP was appointed as the new independent registered public accounting firm for the fiscal year ending June 30, 2027, subject to completion of PwC's standard client acceptance procedures.
  • Director Ronald Taylor informed the Board on August 13, 2026 that he will not stand for re-election at the 2026 annual meeting of stockholders, expected to be held on November 18, 2026.
  • The Board approved the appointment of Carol Burt as lead director, effective November 15, 2026.

Auditor Dismissal and Replacement with PricewaterhouseCoopers

The Audit Committee of ResMed's Board of Directors conducted a competitive review process to evaluate a new independent registered public accounting firm. On August 13, 2026, following completion of that process, the Audit Committee approved the dismissal of KPMG and appointed PwC for the fiscal year ending June 30, 2027, subject to completion of PwC's standard client acceptance procedures. The filing states that during the fiscal years ended June 30, 2026 and 2025, and the subsequent interim period through August 13, 2026, neither the company nor anyone on its behalf consulted with PwC regarding accounting principles or any reportable events.

KPMG Audit Reports Contained No Adverse Opinions or Qualifications

According to the filing, KPMG's reports on ResMed's consolidated financial statements for the fiscal years ended June 30, 2026 and 2025 did not contain any adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope, or accounting principles. The filing further states there were no disagreements with KPMG on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures during those periods and the subsequent interim period through August 13, 2026. KPMG confirmed in a letter dated August 17, 2026 that it agrees with ResMed's statements under Item 4.01(a).

Director Ronald Taylor to Retire; Carol Burt Appointed Lead Director

On August 13, 2026, director Ronald Taylor informed the Board that he will not stand for election at ResMed's 2026 annual meeting of stockholders and intends to retire from the Board, effective at the Annual Meeting, which is expected to be held on November 18, 2026. The filing states that Mr. Taylor's intention to retire is not due to any disagreement with ResMed on any matter relating to the company's operations, policies or practices. In connection with Mr. Taylor's retirement, the Board approved the appointment of Carol Burt as lead director, effective November 15, 2026. A press release relating to these announcements was issued on August 17, 2026.